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Interactions of host cell factors with RNA sequences and structures in the genomes of positive-strand RNA
viruses play various roles in the life cycles of these viruses. Our understanding of the functional RNA elements
present in norovirus genomes to date has been limited largely to in vitro analysis. However, we recently used
reverse genetics to identify evolutionarily conserved RNA structures and sequences required for norovirus
replication. We have now undertaken a more detailed analysis of RNA structures present at the 3 extremity
of the murine norovirus (MNV) genome. Biochemical data indicate the presence of three stable stem-loops,
including two in the untranslated region, and a single-stranded polypyrimidine tract [p(Y)] of variable length
between MNV isolates, within the terminal stem-loop structure. The well-characterized host cell pyrimidine
binding proteins PTB and PCBP bound the 3-untranslated region via an interaction with this variable
sequence. Viruses lacking the p(Y) tract were viable both in cell culture and upon mouse infection, demon-
strating that this interaction was not essential for virus replication. However, competition analysis with
wild-type MNV in cell culture indicated that the loss of the p(Y) tract was associated with a fitness cost.
Furthermore, a p(Y)-deleted mutant showed a reduction in virulence in the STAT1/ mouse model, high-
lighting the role of RNA structures in norovirus pathogenesis. This work highlights how, like with other
positive-strand RNA viruses, RNA structures present at the termini of the norovirus genome play important
roles in virus replication and virulence.
Noroviruses are now well established as the leading cause of
nonbacterial gastroenteritis in the developed world (reviewed
in references 31 and 34), but recent studies have also demon-
strated links with more significant clinical disease, e.g., exac-
erbation of inflammatory bowel disease (20), an outbreak of
necrotizing enterocolitis (41), and the induction of seizures in
neonates (8). The understanding of norovirus translation, rep-
lication, and virulence has lagged behind that for other viruses
due to the inability to propagate human noroviruses efficiently
in tissue culture. Recent advances in the field have led to the
generation of norovirus replicons (5, 6), the demonstration
that human norovirus RNA is infectious in tissue culture (13),
and an unconfirmed report that a highly differentiated cell
culture system can be infected with human noroviruses (38).
Although many caliciviruses have been used as models for the
study of human noroviruses (reviewed in reference 42), the
identification of murine norovirus (MNV) in 2003 (19) led to
unprecedented advances in the analysis of many aspects of
norovirus biology, as to date this is the only norovirus which
replicates efficiently in tissue culture. In addition, the recent
development of reverse genetic systems for murine norovirus
(7, 44) has allowed the identification of a virulence determi-
nant in the major capsid protein (1) and the first identification
of functional RNA sequences/structures in the norovirus ge-
nome (35).
The murine norovirus genome carries four potential open
reading frames (ORFs) (Fig. 1A). ORF1 encodes a large
polyprotein which is posttranslationally cleaved by the virus-
encoded protease (NS6) into several proteins which are in-
volved in various aspects of genome replication (37). ORF2
and ORF3 code for the major and minor capsid proteins VP1
and VP2, respectively. In addition, the MNV genome is also
known to contain a fourth potential ORF (Fig. 1A) (ORF4),
which is highly conserved between numerous strains (40) and
whose expression and function have yet to be examined.
Due to the limited coding capacity of their genomes, small
positive-strand RNA viruses rely heavily on host cell nucleic
acid binding proteins for efficient genome translation and rep-
lication (reviewed in reference 22). These host cell factors
often play many roles in the virus life cycle by interacting with
specific RNA sequences and/or structures present within the
viral genome. Such factors are also a major determinant of
viral tropism, as their relative expression levels may determine
the efficiency with which a virus can replicate in a particular
tissue and, as a result, cause disease. Previous work with hu-
man norovirus has identified several host factors interacting
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FIG. 1. The murine norovirus genome contains three 3-terminal stem-loop RNA structures. (A) Schematic representation of murine norovirus
genome, highlighting the four predicted open reading frames and the mature replicase proteins produced from ORF1. (B) Predicted RNA
secondary structure of the 3 end of the MNV genome. The positions of the RNase cleavage sites, as determined by limited RNase digestion
followed by primer extension, are highlighted on the bioinformatically predicted structure for the MNV 3 end. The genetic sequence variation of
38 published murine norovirus 3-end sequences is also provided, highlighting those bases which either are invariant, show signs of covariation, vary
but maintain base pairing, or vary without maintaining base pairing. ClustalW analysis was performed using all available murine norovirus
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with the 5 and 3 ends of the viral genome (15, 16). Although
a recent study clearly indicated that some cellular factors are
potentially involved in norovirus genome circularization (32),
the identities of these and the functions of the known binding
proteins have yet to be determined.
Our previous studies using computational analysis resulted
in the identification of several highly conserved RNA struc-
tures at various positions in the MNV genome (35). Further-
more, preliminary analysis using reverse genetics demon-
strated that these RNA structures played an important role in
unknown aspects of the MNV life cycle. We have now ex-
tended this analysis to perform a more detailed characteriza-
tion of the RNA structures present at the 3 end of the MNV
genome, identifying sequences and structures important for
replication in tissue culture. We have also demonstrated that a
polypyrimidine-rich [p(Y)] tract, present as a single-stranded
terminal loop, is nonessential for virus replication in tissue
culture but contributes to virulence in the STAT1/ mouse
model of MNV pathogenesis. This is the first report of RNA
structures playing a role in the virulence of any member of the
Caliciviridae family.
MATERIALS AND METHODS
Cells and antibodies. Murine macrophage RAW 264.7 cells and baby hamster
kidney cells expressing T7 polymerase (BSR-T7 cells) (3) were maintained at
37°C and 10% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal calf serum and an antibiotic cocktail of penicillin (100 SI units/ml) and
streptomycin (100 g/ml). Bone-derived macrophages (BMMs) from BALB/c
mice were isolated from the thigh bone, differentiated, and maintained as de-
tailed previously (27). Rabbit polyclonal antibodies against the MNV NS7 poly-
merase and capsid protein were developed in the laboratory (7) and obtained
from Herbert Virgin (Washington University in St. Louis), respectively.
Protein expression and purification. For the purification of glutathione S-
transferase–PTB (GST-PTB), Escherichia coli DH5 cells were transformed with
the pGEX6P-1 PTB plasmid, provided by Richard Jackson (University of Cam-
bridge, United Kingdom). Cells from a single colony were grown in LB at 37°C
to an optical density at 600 nm (OD600) of 0.6. Isopropyl--D-thiogalactopyrano-
side (IPTG) was added at a final concentration of 0.1 mM, and protein expres-
sion was induced for 2 h. The cells were lysed using a French press under high
pressure (108 Pa) in phosphate-buffered saline (PBS) containing 0.5 mM dithio-
threitol (DTT), 10 mM EDTA, 3 g/ml leupeptin and pepstatin, 1% Triton
X-100, and 1 mM phenylmethylsulfonyl fluoride (PMSF). The clarified lysate was
passed through a glutathione-Sepharose column and washed with PBS contain-
ing 0.5 mM DTT, 10 mM EDTA, and 1% Triton X-100. A second wash with 50
mM Tris, pH 8.0, 150 mM NaCl, and 0.5 mM DTT followed. The protein was
then eluted in 10 mM reduced glutathione, 50 mM Tris, pH 8.0, 150 mM NaCl,
and 0.5 mM DTT and dialyzed against 50 mM HEPES, pH 7.6, 1 mM DTT, 1
mM MgCl2, and 20% glycerol. His-PCBP was purified by transformation of E.
coli JM109 cells with the pQE30:PCBP1 and pQE:PCBP2 plasmids for His-
PCBP1 and His-PCBP2, respectively (kindly provided by Bert Semler, University
of California, Irvine). Cells from a single colony were grown in LB at 37°C to an
OD600 of 0.6. IPTG was added at a final concentration of 0.1 mM, and protein
expression was induced for 2 h. For His-PCBP1 and His-PCBP2, the cells were
pelleted and resuspended in lysis buffer (50 mM Tris, pH 8.0, 20% glycerol, 500
mM NaCl) containing lysozyme (1 mg/ml). The cells were incubated on ice for 30
min and sonicated for complete lysis. Protein purification was performed using
Ni-nitrilotriacetic acid (Ni-NTA; Qiagen) according to the manufacturer’s in-
structions. His-PCBP1 and His-PCBP2 preparations were dialyzed against 50
mM Tris, pH 7.5, 100 mM KCl, 1 mM DTT, 0.05 mM EDTA, and 5% glycerol.
All proteins were stored at 80°C until required, and the protein concentration
was determined using the BCA assay (Pierce).
Plasmid constructs. The construction of the wild-type MNV cDNA constructs
[wild type and wild type (v)] was described previously (1, 7), as was that of SL3
ssm (described as m54 in reference 35). Clones SL2 GA, SL3, SL23, SL3
ssm R, SL3 GNRA, SL3 GNRA (v), and SL3 AAAA were generated by overlap
mutagenic PCR (primer details are available upon request), using KOD Hi-
Fidelity Taq polymerase (Merck Biosciences).
Virus recovery by reverse genetics. Virus recovery using reverse genetics was
performed using BSR-T7 cells for transfection and RAW 264.7 cells for virus
titration, as described in detail previously (7). Briefly, 1 g of full-length viral
cDNA clone (e.g., SL3 ssm R) was transfected, using the Lipofectamine 2000
transfection reagent (Invitrogen), into BSR-T7 cells previously infected with a
recombinant fowlpox virus expressing T7 RNA polymerase at a multiplicity of
infection (MOI) of approximately 0.5. After 24 h, cells were freeze-thawed (at
80°C) to release virus particles. The thawed lysate was clarified and filtered
(0.22-m filter) before 50% tissue culture infective dose (TCID50) titrations
were undertaken with RAW 264.7 cells. The viral TCID50 was determined by
visual inspection of the cell cultures at 5 days postinfection. Stocks of high-titer
passage 1 virus for experimentation were generated by infecting a 60% mono-
layer of RAW cells at an MOI of 0.01. Virus was similarly extracted, but at 48 h
postinfection. Viruses for in vivo experimentation were further concentrated by
ultracentrifugation at 100,000  g for 4 h prior to resuspension in tissue culture
media. The correct sequences of all viruses generated during this study were
confirmed by sequencing of viral RNA from infected cells prior to use.
RNA structure probing and footprinting analysis. RNA structure probing was
performed using RNases V1, A, T1 (Ambion), and T2 (MoBiTec GmbH). A
total of 1 g of in vitro-transcribed, gel-purified, and refolded RNA (65°C for 10
min followed by cooling to room temperature) was mixed with yeast RNA and
structure buffer provided with the RNases (Ambion). Digestions were performed
at 30°C for 10 min with appropriate enzyme concentrations to allow single-hit
kinetics. The reactions were stopped using inactivation/precipitation buffer,
RNA precipitated, and subsequently washed with 70% ethanol and resuspended
in 10 l of nuclease-free water. Two microliters of this RNA was used for primer
extension, using end-labeled primers and avian myeloblastosis virus (AMV)
reverse transcriptase as described by the manufacturer (Promega). A sequencing
ladder generated using the same primer was run along with the primer extension
products in a 7 M urea–6% acrylamide sequencing gel. The gel was dried, and the
radioactive signal was monitored using a phosphorimager.
For RNA footprinting analysis, RNA was incubated with a 10-fold molar
excess of protein (GST-PTB, GST, or His-PCBP2) for 15 min prior to subse-
quent RNase digestions and primer extensions, performed as described above.
Protein storage buffer (see above for further details) or GST protein was used to
control for any nonspecific effects on the primer extension reaction.
EMSAs. All radioactive probes were generated by in vitro transcription of PCR
products containing the region of interest under the control of a T7 RNA
polymerase promoter in the presence of 32P-labeled UTP. All RNA probes were
gel purified using urea-PAGE. Radioactively labeled RNA was excised, eluted,
and precipitated prior to quantification by spectrophotometry. RNA was re-
folded by heat denaturation followed by slow annealing (	1°C/min) prior to use.
The 7.5-l electrophoretic mobility assay (EMSA) reaction mixtures contained
85 nM radioactive RNA probe, GST-PTB or His-PCBP2 at various concentra-
tions (see figures for more details), 0.67 g/l yeast tRNA (Ambion), 50 mM
HEPES, pH 7.6, 25 mM KCl, 2.5 mM MgCl2, 1 mM DTT, and 4% glycerol. All
reaction mixtures were incubated for 10 min at 30°C, and the mixtures were
separated in a 4% acrylamide gel (acrylamide:bis-acrylamide, 19:1) containing
5% glycerol. The EMSA gels were dried and visualized on a phosphorimager
screen. Band quantification was performed using the ImageQuant 5.0 software
package (Molecular Dynamics).
Analysis of viral growth kinetics. Growth curves were performed to assess the
single and multistep growth kinetics for the wild-type, wild-type (v), SL3 GNRA,
and SL3 GNRA (v) viruses. Single-step growth curves were performed using an
sequences in the NCBI database (details available on request). The stop codon of the VP2 coding sequence in SL1 is also highlighted. (C to F)
In vitro-transcribed RNA encompassing SL1, -2, and -3, with a poly(A) tail of 27 nucleotides in length, was subjected to limited RNase digestion
with dilutions of RNases and to subsequent primer extension analysis. A sequencing ladder obtained using the same primer allows the identification
of the RNase cleavage sites. Analysis was performed a minimum of three times, and one representative gel is shown. Nucleotide positions are
numbered according to their positions in the murine norovirus genome. Note that data are shown for regions containing RNase cleavage sites only.
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initial MOI of 4, with samples taken in triplicate for TCID50 titration and
singularly for Western blot analysis, at 0, 4, 6, 8, 12, and 24 h postinfection (hpi).
Multistep growth curve analysis was performed using an MOI of 0.01, with
harvest at 0, 6, 12, 24, and 48 hpi. RAW 264.7 cells were plated in 2-cm2 wells at
a density of 2  105/well, while BMMs were plated at double this density (4 
105/well).
Viral sequence analysis. Sequences were aligned using the ClustalW program
imbedded in the AlignX subprogram of Vector NTI 11 (Invitrogen). RNA
structure predictions were performed using the online mfold and Vienna soft-
ware, available at http://mfold.bioinfo.rpi.edu/cgi-bin/rna-form1.cgi (48) and
http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi, respectively.
Viral competition analysis. Wild-type and SL3 GNRA viruses were mixed at
a 1:1 ratio (based on TCID50) and used to infect RAW 264.7 cells (1.2 106/well
in a 9-cm2 dish) at an overall MOI of 0.01. At 48 h postinfection, the virus was
extracted as detailed above, and the resultant mixed population was used to
infect an equivalent dish of RAW cells at a low MOI (approximately 0.01). RNAs
were extracted for sequencing after an additional passage of the mixed popula-
tion at a high MOI (
1) in RAW cells. The 3 end of the MNV genome was
sequenced to quantify the relative abundances of both wild-type and SL3 GNRA
viruses. The process was repeated for five passages, with virus and RNA being
extracted at each step. As additional controls, both wild-type and SL3 GNRA
viruses were passed alone on RAW cells for 5 rounds of infection, using an
identical passage regimen. These viruses were also equivalently sequenced to
confirm the stability of wild-type and SL3 GNRA 3 sequences.
Virulence studies. Sex-matched STAT1/ mice (Taconic) were inoculated by
oral gavage with 1,000 TCID50 of either wild-type (v) or SL3 GNRA (v) virus
(group size, 8 males and 8 females per virus). Mock inoculations for the negative
control group were performed using an uninfected lysate from RAW 264.7 cells
prepared in an identical manner to that for the virus stocks (group size, 6 males
and 3 females). Animals were monitored daily for the onset of disease, which is
characterized by weight loss, piloerection, anorexia, and eye discharge. The
development of serious MNV-induced disease is characterized by serious weight
loss, ataxia, moribundity, and eventually death. Where possible, the development
of serious disease prompted euthanasia to avoid undue suffering to the animal.
A humane end point of 25% weight loss was also set. On days 3 and 5 postin-
fection, 2 males and 2 females from the two virus groups were euthanized, and
the following tissues and samples were removed and placed in Trizol solution
(Invitrogen) during postmortem: spleen, mesenteric lymph node, kidney, liver,
small intestine, heart, lung, and feces (removed in situ from the colon). Equiv-
alent tissues were taken from animals in the mock lysate group at 14 days
postinfection, which represented the end of the experiment due to lab restric-
tions as well as the outcome and severity of infection. RNA was extracted from
tissues as detailed in the Trizol manufacturer’s instructions.
Quantitative real-time reverse transcription-PCR. RNA was reverse tran-
scribed to cDNA by use of oligonucleotide IC464 (CAAACATCTTTCCCTTG
TTC) and AMV reverse transcriptase (Promega) as detailed in the manufactur-
er’s instructions. cDNA was amplified by real-time PCR, using qPCR master mix
(Eurogentec) and an ABI 7900 real-time PCR machine. Briefly, cDNA was
mixed with 2 buffer and primers IC464 and IC465 (TGGACAACGTGGTGA
AGGAT) in the PCR plate, heat denatured to 95°C for 10 min, and subjected to
40 cycles of 94°C for 15 s, 58°C for 30 s, and 72°C for 30 s. Viral genome copy
number was calculated by interpolation from a standard curve. This was gener-
ated using serial dilutions of standard RNA representing nucleotides 1085 to
1986 of the MNV genomic RNA, generated by in vitro transcription. Standard
RNA was PAGE purified, phenol chloroform extracted, ethanol precipitated,
resuspended in nuclease-free water, and quantified using spectrophotometry.
RESULTS
The MNV genome contains three stem-loop structures at
the 3 end. Our previous bioinformatic analysis identified the
presence of a region of significant synonymous codon suppres-
sion at the 3 end of the VP2 coding region, as well as con-
served RNA structures within the 3-untranslated region (3-
UTR) (Fig. 1) (35). In addition, alignment of a number of
previously published sequences demonstrated the existence of
polymorphism in the length of the polypyrimidine tract [re-
ferred to herein as the p(Y) tract] predicted to lie within the
terminal loop sequence (data not shown). To further confirm
the presence of defined RNA structures within the 3 end of
the MNV genome, we used biochemical structure probing with
conformation-specific RNases, followed by reverse transcrip-
tion to identify the positions of RNase digestion (Fig. 1B–F).
This confirmed the presence of the three bioinformatically
predicted stem-loop structures, depicted as SL1 to SL3 in Fig.
1B. Only a limited number of double-strand-specific RNase V1
digestion sites were observed in the 5-proximal stem-loop
(SL1), suggesting that these regions are not accessible to di-
gestion or do not adopt the correct helical conformation re-
quired for efficient cleavage (24). In addition, some regions of
SL1 predicted to be double stranded were sensitive to cleavage
with single-strand-specific RNases (e.g., G7286), possibly re-
flecting the inherent instability or flexibility of the RNA sur-
rounding that particular sequence. While it is feasible that the
predicted structure for SL1 may be incorrect, the high degree
of conservation and the presence of (limited) covariation in
this stem (Fig. 1B) argue for alternative interpretations. In
addition, the predicted thermodynamic stability of SL1 is very
favorable, presenting further supporting evidence for its exis-
tence (data not shown). The structures of SL2 and -3 were
better defined using biochemical structure probing, with clear
regions showing sensitivity to single- and double-strand-spe-
cific RNases (Fig. 1B–F).
Functional requirements of RNA structures in the MNV 3
UTR. To determine the functions of the RNA structures
present in the 3 UTR and to identify sequences and/or struc-
tures required for norovirus replication and virulence, a panel
of deletion and point mutations in the MNV1 3 end were
generated (Fig. 2). The SL3 ssm (secondary structure mutant)
mutation has been described previously and referred to as m54
(35). Infectious clones containing the various mutations in the
MNV 3 end were transfected into cells previously infected
with a helper virus expressing T7 RNA polymerase as de-
scribed previously (7), and the ability to recover infectious
virus was determined (Table 1). Complete deletion of the
GA-rich tract of SL2 or deletion of SL3 or both SL2 and -3
rendered the clone noninfectious (Table 1), confirming that
the integrity of the entire 3 UTR is critical for function. In
addition, we failed to recover any viable virus after repeated
“blind” passage of the samples obtained from the virus recov-
ery transfections, confirming the debilitating effects of the de-
letion mutations.
To exclude the possibility that the debilitating effect of de-
letion of the GA-rich tract of SL2 on MNV replication was
simply related to alterations in the spatial relationship of SL1
and SL3, which would be 10 nucleotides closer together in the
SL2 virus than in the wild-type virus, we also examined the
effect of sequence alterations to SL2 on MNV replication (SL2
ssm) (Fig. 2). The SL2 ssm virus was designed to replace the
GA-rich sequence with an unrelated sequence of different
composition which would also disrupt the stability of SL2 with-
out affecting the structure of SL1 and SL3. As with the SL2
GA virus, the mutations introduced into the SL2 ssm mutant
were debilitating for MNV replication, and no infectious virus
could be recovered, despite repeated blind passage of the virus
recovery transfections.
We have previously demonstrated that alterations to the
structure of SL3 are debilitating to MNV replication (35), as
the mutant referred to herein as SL3 ssm (Fig. 2) (called m54
in reference 35) failed to produce detectable levels of infec-
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tious virus after the initial reverse genetics recovery transfec-
tion (Table 1). To determine whether the sequence of or base
pairing in the stem region of SL3 was required for replication,
a number of restorative mutations were introduced into SL3
ssm to restabilize the structure (SL3 ssm R) (Fig. 2). Restora-
tion of the SL3 base pairing did not, however, result in the
recovery of infectious virus, indicating that at least some of the
sequence within the stem also plays an important role. Inter-
estingly, however, repeated blind passage of the parental SL3
ssm mutant resulted in the generation of a virus which had
regained the ability to replicate. Sequence analysis of the iso-
lated virus, referred to as SL3 ssm NR (for natural revertant),
indicated that the initial mutations in the stem were still
present but that a substantial 8-nucleotide deletion of the p(Y)
tract had occurred (Fig. 2).
The 3 p(Y) tract binds the cellular polypyrimidine tract
binding protein and poly(rC) binding protein. Two well-char-
acterized host cell factors with the capacity to bind pyrimidine-
rich sequences are poly(rC) binding proteins (isoforms 1 and 2
[PCBP1/2]) (25) and polypyrimidine tract binding protein
FIG. 2. Murine norovirus 3-end mutants. Schematic representation of the MNV 3 end, highlighting the various deletion and point mutants
under study. The diagram at the top left highlights the nucleotide positions of the various stem-loops, SL1 to SL3, and the GA-rich sequence in
SL2 deleted in the corresponding mutants. The positions of the nucleotide alterations in SL2 ssm, SL3 ssm, and SL3 ssm R are highlighted with
filled circles or squares, with the corresponding changes introduced shown offset in the open circles or squares. The predicted secondary structures
of SL3 in the SL3 ssm NR mutant, with the deleted sequence boxed, in SL3 GNRA, and in SL3 AAAA are also shown. Note that for the purposes
of this figure, the base pairing predicted to occur between the poly(A) tail and the MNV 3 UTR has been omitted. In addition, the schematics
for SL2 ssm, SL3 ssm, SL3 ssm R, and SL3 ssm NR are for illustrative purposes only, since the predicted secondary structure is significantly
modified by the introduced mutations.
TABLE 1. Effects of mutations in MNV 3 end on virus recovery,
using reverse genetics
Mutation Description Recoverya
SL2 GA Deletion of stem-loop 2 positions 7311 to 7320 No
SL3 Deletion of stem-loop 3 position 7330 to poly(A) No
SL2  3 Deletion of stem-loops 2 and 3 from position
7308 to poly(A)
No
SL2 ssm Mutation disrupting secondary structure in SL2
stem and loop
No
SL3 ssm Mutation disrupting secondary structure in SL2
stemb
No
SL3 ssm R Secondary structure reversion mutant of SL3 ssm No
SL3 GNRA Substitution of polypyrimidine tract loop in SL3
with GNRA tetraloop
Yes
SL3 AAAA Substitution of polypyrimidine tract loop in SL3
with AAAA tetraloop
Yes
a Virus recovery is defined as the ability to generate virus capable of generating
clear cytopathic effect in RAW 264.7 cells by 5 days postinfection. The limit of
detection of this assay was 	50 TCID50/ml. Each recovery was repeated a
minimum of three times and was scored as negative if no detectable virus was
observed. The yields of wild-type, SL3 GNRA, and SL3 AAAA cDNA clones
were typically 
104 TCID50 per 35-mm dish.
b A natural revertant of this virus (SL3 ssm NR) was generated following
multiple blind passages of this virus in permissive cells (as described in the main
text).
VOL. 84, 2010 MURINE NOROVIRUS 3 UTR CHARACTERIZATION 2863
(PTB) (33). These proteins have previously been identified as
components of a ribonucleoprotein complex (RNP) which can
form on the 5 and 3 ends of the Norwalk virus genome (15,
16). We therefore examined the ability of recombinant forms
of PCBP and PTB to bind to the 3 UTR of the MNV genome
by using EMSA (Fig. 3A and D). Our data indicate that both
PCBP1 (data not shown) and PCBP2 (Fig. 3A) can interact
with the 3 end of the MNV genome to form a stable RNP
complex. Recombinant PTB was also able to form a stable
RNP complex with the 3 end of the MNV genome (Fig. 3D),
and as in the case of PCBP, the specificity of the interaction
was confirmed by both the inability of heterologous competitor
RNA to compete for RNP complex formation and, conversely,
the ability of unlabeled homologous RNA to compete (data
not shown). Given the previously reported propensity of one of
these host cell factors to interact with single-stranded pyrimi-
dine-rich regions (25), we examined the role of the variable
p(Y) tract in PCBP and PTB binding by EMSA, using a 3 end
derived from SL3 in which the p(Y) tract was replaced by a
GNRA tetraloop (26) (shown as SL3 GNRA in Fig. 2). EMSA
data demonstrated a reduced ability for RNP complex forma-
tion on the SL3 GNRA probe compared to a wild-type probe
(Fig. 3B, C, E, and F), indicating that the p(Y) tract is impor-
tant for the binding of PCBP and PTB. The binding site for
PTB was also confirmed using biochemical RNase footprinting
analysis, which demonstrated that the p(Y) tract was the major
PTB and PCBP binding site (Fig. 4). Binding of PTB and
PCBP2 to the MNV 3 end did not result in any major effect on
the folding of SL1, SL2, or SL3, as is evident from RNase
sensitivity mapping (data not shown).
The 3 p(Y) tract is not required for MNV replication in
tissue culture. The isolation of naturally generated replication-
FIG. 3. PCBP2 and PTB binding to the murine norovirus 3 end. EMSAs demonstrated the ability of recombinant PCBP2 and PTB to interact
with the wild-type MNV 3 end (A and D, respectively) or the SL3 GNRA 3 end (B and E, respectively). Quantification of the corresponding
EMSA products is expressed as the percentage of probe in any complex with either recombinant PCBP2 (C) or PTB (F). The positions of the free
probe (P) and various RNA-protein complexes (C, CI, CII, and CIII) are also highlighted.
FIG. 4. Biochemical footprinting confirmation of PTB binding site.
Polyacrylamide gel analysis was performed on primer extension prod-
ucts obtained from transcripts digested with the single-strand-specific
RNase T2 in the presence of PCBP2 (A) or GST, GST-PTB, or buffer
alone (B). A sequencing ladder was run alongside, obtained using the
same primer, to highlight the sequence protected by PCBP2 and PTB
binding (boxed). (C) Schematic representation of SL3 highlighting the
PCBP2 and PTB binding site identified by footprinting analysis.
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competent MNV carrying a deletion within the p(Y) tract
suggests that this region may not be required for virus repli-
cation in tissue culture. However, this deletion occurred in a
mutant containing several destabilizing mutations in the SL3
stem sequence (SL3 ssm in Fig. 2). To specifically analyze the
functional requirements for the p(Y) tract, we generated two
cDNA clones bearing mutations in the p(Y) tract of SL3,
namely, SL3 GNRA, containing a complete replacement of the
p(Y) tract with a GNRA stem-loop-stabilizing sequence
(GUAA in reference 26), and the SL3 AAAA mutant, con-
taining a tetra-A loop in place of the p(Y) tract (Fig. 2).
Reverse genetics recovery of these viruses indicated that they
were both replication competent, producing similar levels of
virus to those for the wild-type infectious clone (Table 1). To
examine any differences in growth kinetics and protein produc-
tion rates, we performed single-cycle and multicycle growth
curve analysis of SL3 GNRA and compared it to wild-type
virus (Fig. 5A and B, respectively). No significant differences
were apparent in the rates at which infectious virus was pro-
duced from RAW 264.7 murine macrophage cells infected with
SL3 GNRA or wild-type virus during both single-cycle and
multicycle growth (Fig. 5). Analysis of protein production by
Western blot analysis for the viral polymerase NS7 and the
major capsid protein VP1 showed a small but reproducible
increase in NS7 production in cells infected with SL3 GNRA
compared to that in cells infected with wild-type virus (Fig. 5A
and B). A reproducible loss of the cellular glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) protein was also ob-
served during the later stages of viral single-cycle infection
(Fig. 5A).
Deletion of the 3 p(Y) tract results in a fitness cost to MNV
replication. The observation that all sequenced MNV isolates
identified to date possess a p(Y) tract in the 3 UTR, although
the sequence and length can vary (data not shown), suggests
that the presence of the 3 p(Y) tract confers some fitness
benefit to MNV. However, our reverse genetics and growth
curve data indicated that it was nonessential for growth in
RAW 264.7 murine macrophage cells. The stability of the SL3
GNRA mutant was therefore examined over repeated passage
in tissue culture at a low multiplicity of infection. Sequence
analysis of the virus population indicated that the GNRA mu-
tation was still present after repeated passage in tissue culture
(data not shown). To further determine if the deletion of the
p(Y) tract resulted in a fitness cost that was not apparent in the
absence of additional external selective pressures, we exam-
ined the ability of the SL3 GNRA mutant virus to replicate in
the presence of wild-type virus. Wild-type and SL3 GNRA
viruses were mixed at a ratio of 1:1 and subsequently repeat-
edly passaged in murine RAW 264.7 macrophage cells. The
sequence of the 3 UTR was subsequently analyzed during the
various passages by sequencing of the viral population (Fig. 6).
Although the sequence obtained after passage 1 showed that
FIG. 5. Viral growth kinetics of wild-type and SL3 GNRA murine noroviruses in tissue culture. Single-cycle (A) and multicycle (B) growth
kinetics of wild-type virus and the virus lacking the 3 p(Y) tract (SL3 GNRA) were determined with the murine macrophage cell line RAW 264.7.
Cells were infected at multiplicities of infection of 4 and 0.01 (A and B, respectively), and samples were taken at various time points postinfection.
The yield of infectious virus was determined by TCID50 titration in RAW264.7 cells and expressed as TCID50/ml. Infections were performed in
triplicate, and the averages were plotted along with standard deviations. Viral protein synthesis was also examined by preparing protein extracts
and subsequently analyzing them by Western blotting of 10 g of protein for the viral polymerase (NS7), viral capsid (VP1), or an endogenous
host cell protein (GAPDH). Note that the absence of GAPDH at 12 h postinfection during the single-cycle growth curve analysis was the likely
result of the effect of virus infection on host cell protein synthesis.
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both wild-type and SL3 GNRA viruses were present at com-
parative levels (as evident by the heterogeneity at the first,
third, and fourth nucleotide positions), by passage 5 the se-
quence of the wild-type virus predominated (Fig. 6), indicating
that the presence of the 3 p(Y) tract conferred a competitive
advantage to this virus during MNV replication in tissue cul-
ture. Equivalent observations were recorded in two indepen-
dent repeats of this 1:1 experiment, and even at a 1:10 ratio
(wild type to SL3 GNRA) (data not shown).
The 3 p(Y) tract contributes to MNV virulence. To deter-
mine if the 3 p(Y) tract plays a role in viral virulence in vivo,
we first introduced the SL3 GNRA 3 end into an MNV1
cDNA clone containing two mutations (G2151A and
A5941G). This sequence more faithfully represents the con-
sensus sequence isolated from infected STAT1/ mice (re-
ferred to as CW1.P1 in references 1 and 19), and we have
previously demonstrated that the A5941G mutation, which
results in a change of glutamate 296 to lysine in the major
capsid protein VP1, is sufficient to restore virulence to the
tissue culture-adapted attenuated strain of MNV (1). As ob-
served in the attenuated virus background, the derivatives of
the wild-type and SL3 GNRA mutant viruses in the virulent
background [wild type (v) and SL3 GNRA (v)] replicated to
similar levels in both RAW 264.7 cells and primary bone mar-
row-derived macrophages (Fig. 7). The role of the 3 p(Y) tract
in viral virulence was then examined by oral inoculation of
STAT1/ mice with the wild-type (v) and SL3 GNRA (v)
viruses (Fig. 8). Control inoculated mice continued to gain
weight throughout the duration of the study, whereas mice
inoculated with wild-type (v) MNV showed statistically signif-
icant weight loss at 4 days postinoculation (P  0.001 by anal-
ysis of variance [ANOVA]) (Fig. 8). In contrast, weight loss in
the SL3 GNRA (v)-inoculated mice was more varied, with
some mice displaying similar weight losses to those of the
wild-type (v) group at 4 days postinfection while others con-
tinued to gain weight in a comparable manner to the mock-
infected group. Significant weight loss in the SL3 GNRA (v)-
infected mice (compared to the control group) was not
observed until 5 days postinfection.
Comparisons of weight losses between SL3 GNRA (v)- and
wild type (v)-inoculated mice showed significant variation at
days 4, 5, and 6 postinfection (P  0.05, P  0.001, and P 
0.001, respectively, by ANOVA) (Fig. 8A), indicating a marked
deviation from normal disease progression. The symptomatic
onset of disease and associated mortality also reflected this
variation between the wild-type and mutant viruses. On day 5
postinfection, 5 of 12 mice infected with wild-type (v) virus had
FIG. 6. Competition analysis of wild-type and SL3 GNRA murine
noroviruses. Sequencing chromatograms were obtained for the virus
population obtained after 1 to 5 passages of a 1:1 mix of wild-type and
SL3 GNRA viruses in RAW 264.7 cells. Cells were infected at an
approximate multiplicity of infection of 0.01 for 48 h before dilution
and passage onto an additional monolayer. For virus sequence analy-
sis, the virus population isolated at each passage was used to infect a
fresh monolayer at a high multiplicity of infection (
3) for 	16 h
before viral RNA was extracted from the cells and sequenced by
reverse transcription-PCR.
FIG. 7. Viral growth kinetics of virulent wild-type and SL3 GNRA
viruses in primary bone-derived murine macrophage cells. Sequence-
verified stocks of wild-type or SL3 GNRA murine norovirus in the
CW1.P1 backbone (see the text for more details) were used to infected
either RAW 264.7 cells or primary bone-derived macrophage cells at a
multiplicity of infection of 0.01 (based on viral titration in RAW 264.7
cells). Infections were performed in triplicate, and samples were taken
at various times postinfection prior to TCID50 titration in RAW 264.7
cells. The average titers were plotted as TCID50/ml, with the standard
deviations also shown.
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succumbed to infection or had passed the established humane
end points and been euthanized, with an additional animal
being moribund. All remaining animals in this group showed
the established clinical signs and symptoms of infection, i.e.,
weight loss, piloerection, discharge from the eyes, associated
depressed motility, and anorexia. In contrast, the SL3 GNRA
(v) group showed noticeable variation in both the onset of
disease symptoms and the establishment of clinical signs. By
day 5, two animals had succumbed to infection, one was mor-
ibund, and three exhibited weight loss and symptoms of dis-
ease. However, six showed no clinical signs or symptoms of
infection (with all weighing more than their individual day 0
weights) (Fig. 8a), which is a significantly greater proportion
than that found in the wild-type-infected control group (P 
0.014 by two-tailed Fisher’s exact test). Note that all animals
infected with SL3 GNRA (v) eventually established disease
symptoms and clinical signs of infection. Postmortem analysis
of animals euthanized for tissue sampling on days 3 and 5
postinfection also highlighted differences between SL3 GNRA
(v)- and wild-type (v)-infected mice, which typically correlated
with the differential weight loss evident in the two groups.
Animals with significant weight loss showed more serious
pathological signs of infection, such as liver and spleen necro-
sis, gastric bloating, and significant dehydration. However,
those animals exhibiting weight gain or reduced weight loss
[found more frequently in SL3 GNRA (v)-infected mice] (Fig.
8A) were often normal upon postmortem. This correlated with
the distribution of viral RNA within various tissues of the host,
which was examined using quantitative real-time PCR (Fig.
8B). While all mice infected with wild-type (v) virus contained
high levels of viral RNA in their tissues on days 3 and 5
postinfection, only 75% of SL3 GNRA (v)-infected mice had
equivalent levels of viral RNA (Fig. 8B; data not shown for day
3, but the trend was comparable). Note that animals were
arbitrarily selected for tissue sampling based on ear tag num-
ber, not the presence of disease. Significantly, the levels of
excreted viral RNA obtained from feces taken from the colon
during postmortem were found to be reduced in the SL3
GNRA (v)-inoculated mice at 3 days postinfection compared
to those inoculated with the wild-type (v) virus (Fig. 8C).
DISCUSSION
The study of RNA-protein interactions required for calici-
virus translation and/or replication has, to date, largely been
limited to in vitro analysis. The well-characterized cellular nu-
cleic acid binding proteins PTB, PCBP, La autoantigen, and
hnRNP L have all previously been reported to interact with the
5 end of the Norwalk virus genome (15), whereas La and PTB,
along with poly(A) binding protein, have also been shown to
interact with the 3 UTR (16). One or more of these host cell
factors or an as yet unidentified factor may be involved in
protein-mediated circularization of the Norwalk virus genome
(32). As is well established for other positive-strand RNA
viruses, host cell factors may similarly interact with RNA struc-
tures and/or sequences within the norovirus genome and play
roles in the viral life cycle. To date, however, no functional
interaction between a host protein and the norovirus genome
has been demonstrated, although it has been shown that the
interaction of PTB with the genome of feline calicivirus (FCV),
another member of the Caliciviridae family, plays some role in
the virus life cycle (18).
In the current study, we aimed to identify and characterize
RNA structures/sequences at the 3 end of the viral genome
that are required for norovirus replication, using MNV as a
model system. The use of MNV as a model system also sub-
sequently allowed us to extend these studies to examine, for
the first time, the role of RNA structures in norovirus viru-
lence. Biochemical analysis of the structure of the 3 end of the
MNV genome revealed that in agreement with our previously
reported bioinformatic analysis (35), the MNV genome con-
FIG. 8. Virulence analysis of wild-type and SL3 GNRA murine
noroviruses in STAT1/ mice. (A) Age- and sex-matched groups of
STAT1/ mice were orally inoculated with 1,000 TCID50 of se-
quence-verified, partially purified wild-type or SL3 GNRA murine
norovirus recovered in the virulent backbone (see the text for details),
and their weight was monitored daily. Control mice were inoculated
with a lysate from cells prepared in a similar manner to that for the
virus stocks (see Materials and Methods for further details). ***, P 
0.001; *, P  0.05 by two-way ANOVA with Bonferroni posttests.
(B) qPCR with tissues; (C) qPCR with feces. The numbers of viral
genome copies were determined by quantitative real-time reverse tran-
scription-PCR. RNAs were extracted from numerous tissues at 5 days
postinfection and from feces at 3 and 5 days postinfection, and the
numbers of genome copies per g of total RNA were determined as
described in Materials and Methods. The means are shown, with stan-
dard errors highlighted. The significant difference recorded at day 3
postinfection was observed using a standard t test.
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tains three putative stem-loops within the 3 end of the viral
genome, one within the VP2 coding region and two within the
UTR, although the stop codon of VP2 also contributes two
nucleotides to SL2 (Fig. 1). SL1 was largely insensitive to
RNase digestion, and only a limited number of cleavage sites
were identified (Fig. 1). Although our current study did not
confirm a functional role for SL1, bioinformatic analysis dem-
onstrates that as with SL2 and SL3, SL1 shows restricted ge-
netic variability compared to neighboring coding sequences,
with covariation to maintain pairing for substitutions occurring
in predicted base-paired regions of the stem (Fig. 1B). The
presence of a functional cis-acting RNA structure within the
VP2 coding region has already been reported for another
member of the Caliciviridae, namely, FCV (36). Previous anal-
ysis demonstrated that although the FCV VP2 protein is re-
quired for infectious virion production, the underlying VP2
coding sequence contains an element (or elements) required in
cis for genome replication to occur (36). The boundaries of this
replication element indeed map exactly to the predicted large
stem-loop structure in this region of VP2 (35), and it is similar
in size and position to SL1 in MNV. Although MNV, FCV,
and GII/4 human noroviruses contain potential RNA struc-
tures within the VP2 coding region, secondary structure ele-
ments do not appear to be universally present in all members
of the Caliciviridae; previous bioinformatic analysis provided
no evidence for conserved RNA secondary structures in the
homologous region for members of the Lagovirus genus (35).
Furthermore, unlike the case with FCV, complete removal of
the VP2 coding sequence from the genome of rabbit hemor-
rhagic disease virus (RHDV) had little effect on virus replica-
tion in tissue culture (23). Recent work has also highlighted
that sequences within the 3 end of the Norwalk virus genome
contain an RNA element or elements which stimulate the in
vitro nucleotidylation of recombinant VPg in the presence of
magnesium chloride (2). This may suggest that similar to pre-
vious reports for poliovirus (11, 29), the norovirus genome may
possess sequences which may function as a template for the
transfer of nucleotide to VPg to allow genome replication.
Clearly, additional data are required to identify the specific
sequences involved and to confirm their role in VPg-depen-
dent genome replication.
The identification of a natural revertant of the SL3 ssm
mutant, with a disrupted terminal stem-loop (SL3) in which the
p(Y) tract was deleted, indicates that this sequence is not
required for MNV replication in vitro. SL3 ssm mutations in
SL3 (in the context of the 3 end of the viral genome) create an
alternative possible RNA structure containing a stable stem in
which the GA-rich sequence of SL2 interacts with the p(Y)
tract of SL3 (data not shown). This base paring in the SL3 ssm
mutant therefore completely disrupts SL2 and SL3. Prediction
of the structure adopted by the SL3 ssm NR 3 end indicates
that the observed deletion in the p(Y) tract allows the forma-
tion of SL2 and the bottom stem of SL3 when the SL3 ssm
mutations are also present (data not shown). These data sug-
gest that the stability and correct formation of SL2 and the
bottom stem of SL3 are critical for MNV replication. Our
previous observation that replacement of the terminal U nu-
cleotide with a C resulted in a complete loss of MNV viability
(7) also indicates that the terminal stem is important for rep-
lication. Combining our current and previous data, we can
conclude that SL2 and the bottom stem of SL3 are essential for
MNV viability. Further studies will be aimed at identification
of the host cell or viral factors which interact with these regions
and determination of the functional defect in viruses bearing
mutations in these regions.
We demonstrated a sequence-specific interaction of
PCBP1/2 and PTB with the variable p(Y) tract in the 3 end of
the MNV genome, although this interaction appears to be
nonessential for virus replication in vitro. A reproducible in-
crease in the levels of proteins produced from a virus lacking
the p(Y) tract was observed, although this clearly had no de-
tectable effect on virus titer (Fig. 5). This might suggest that
the 3 p(Y) tract plays some role in controlling the balance
between viral genome translation and replication or that the
binding of PCBP1/2 and/or PTB to this region has a repressive
effect on virus translation. In addition to the interactions of
PCBP1/2 and PTB with the 3 end reported here, we have
recently shown that PCBP1/2 and PTB also have the ability to
interact with the 5 ends of the MNV genomic and subgenomic
RNAs (I. Karakasiliotis, L. M. W. Chung, and I. Goodfellow,
unpublished data). It is therefore possible that PCBP1/2 or
PTB interacts simultaneously with the 5 and 3 ends of the
MNV genome to result in genome circularization, as is pre-
dicted to occur in Norwalk virus (32), but further studies are
required to examine this in more detail. Despite the ability of
the SL3 GNRA virus to replicate, our competition analysis
indicated that the deletion of the p(Y) tract resulted in a fitness
cost (Fig. 6), which may explain why this region, although
variable in size, is present in all isolates of MNV identified to
date. Although PCBP1/2 and PTB binding was significantly
reduced by the replacement of the p(Y) tract with a GNRA
tetraloop, it was not abolished, as some residual (but specific)
binding activity remained (Fig. 3C and F). Residual binding
may have been sufficient to allow replication to occur in rapidly
dividing cells in cell culture, where the levels of factors such as
PCBP1/2 and PTB are likely to be substantially higher than
those in differentiated tissues in vivo. Other host cell factors
may also be overexpressed in immortalized cells and effectively
complement the lack of PCBP1/2 or PTB binding. Similarly,
the residual PCBP1/2 and PTB binding may also explain the
reduced virulence of the SL3 GNRA virus in the STAT1/
mouse model. Given the additional selective pressures on virus
replication in vivo, one possible explanation for the subsequent
disease progression in mice inoculated with the SL3 GNRA
virus was that viruses regained the p(Y) tract. However, se-
quence analysis of viruses isolated from the various tissues
indicated that reversion or restoration of the p(Y) tract had
not occurred either in those animals that lost weight equiva-
lently to wild-type-infected mice or in those that did not (data
not shown). The evidence for a functional role of the p(Y) tract
for in vivo replication may indeed contribute to the ability of
MNV to establish persistent infections in immunocompetent
hosts (17, 40). Indeed, a more evident role for the p(Y) tract
may be revealed in future challenge experiments using immu-
nocompetent mice in place of the STAT1/ mice used in the
current study. To date, however, a reverse genetics system for
an MNV isolate which results in a persistent infection has yet
to be established.
The presence of a p(Y) tract within the 3 UTR of MNV is
not unique to MNV, as many positive-strand RNA viruses
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contain such elements. The 3UTR of hepatitis C virus (HCV)
also contains a p(Y) tract, of 	200 nucleotides in length (21,
39, 45), which interacts with hnRNPC and PTB (10). In con-
trast to our current studies with MNV, however, the HCV p(Y)
tract is essential for HCV replication in tissue culture, requir-
ing a minimum length of 26 U residues for replication (9). The
3 p(Y) tract of HCV has also been shown to be important for
viral virulence, as deletions inhibit virus recovery after hepatic
inoculation of in vitro-transcribed viral RNA (46). The function
of the HCV 3 p(Y) tract is as yet unknown, but data indicate
that it may play a stimulatory role in viral internal ribosome
entry site (IRES)-mediated translation (43).
The attenuation of positive-strand RNA viruses through the
modification of RNA structures present in the 5 or 3 end of
the viral genome has been well documented for many different
viruses. For example, attenuation of West Nile virus can be
achieved through the modification of sequences within the
3-terminal stem-loops (47). Some deletions in the 3 UTR of
foot-and-mouth disease virus (FMDV) also affect virulence but
not tissue culture growth, and in this case, they were found to
elicit a protective immune response in swine (30). One of the
best-characterized examples of where the interaction of a host
cell factor with viral RNA structures plays a role in pathogen-
esis is in the attenuation of poliovirus, where mutations in the
5 UTR of vaccine strains affect the binding of PTB (14) and
other translation initiation factors (28). In vivo studies also
confirmed the importance of the interaction of PTB with these
sequences for poliovirus neurovirulence (12). Here we de-
scribe how reverse genetics can also be used as a potential
method to attenuate murine norovirus via the modification of
noncoding sequences. Previous studies have clearly indicated
that live virus vaccination against noroviruses can be effective
(4), and hence, once a full infectious tissue culture system is
established, this and similar approaches which generate live
attenuated noroviruses may provide a mechanism for vaccinat-
ing against human norovirus infection. Clearly, such studies
will only be feasible once the “missing link” which allows hu-
man norovirus replication to occur in tissue culture has been
identified; recent studies suggest that this is at the level of virus
entry and uncoating (13). Until that point, studies such as that
described here will continue to add to our growing understand-
ing of norovirus-host cell interactions, potentially leading to
novel approaches for the control of this economically impor-
tant pathogen.
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